Omega Diagnostics Group PLC Exercise of Options and Total Voting Rights (0423C)
14 October 2020 - 5:45PM
UK Regulatory
TIDMODX
RNS Number : 0423C
Omega Diagnostics Group PLC
14 October 2020
14 October 2020
OMEGA DIAGNOSTICS GROUP PLC
("Omega" or the "Company" or the "Group")
Exercise of Options and Total Voting Rights
Omega Diagnostics (AIM: ODX), the medical diagnostics company
focused on CD4, infectious diseases and food intolerance testing,
announces that it has allotted 290,000 new ordinary shares of 4
pence each in the capital of the Company ("Ordinary Shares")
following the exercise of share options and the subsequent sale of
shares by an ex-employee.
Application will be made to the London Stock Exchange for the
290,000 new Ordinary Shares to be admitted to trading on AIM
("Admission") and it is expected that Admission will become
effective and trading will commence at 8.00 a.m. on 20 October
2020.
After Admission, the total number of Ordinary Shares in issue
will be 179,006,153 and the total number of voting rights will
therefore be 179,006,153. This figure may be used by shareholders
as the denominator for the calculations by which they will
determine if they are required to notify their interest in, or a
change to their interest in, the share capital of the Company under
the FCA's Disclosure and Transparency Rules.
The information contained within this announcement is deemed by
the Company to constitute inside information stipulated under the
Market Abuse Regulation (EU) No. 596/2014.The below notification is
made in accordance with the requirements of the EU Market Abuse
Regulation.
Contacts:
Omega Diagnostics Group PLC Tel: 01259 763 030
Colin King, Chief Executive www.omegadiagnostics.com
Kieron Harbinson, Group Finance Director
finnCap Ltd Tel: 020 7220 0500
Geoff Nash / Teddy Whiley (Corporate
Finance)
Alice Lane (ECM)
Walbrook PR Limited Tel: 020 7933 8780 or
omega@walbrookpr.com
Paul McManus Mob: 07980 541 893
Lianne Cawthorne Mob: 07584 391 303
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TVRFFSSMLESSELS
(END) Dow Jones Newswires
October 14, 2020 02:45 ET (06:45 GMT)
Omega Diagnostics (LSE:ODX)
Historical Stock Chart
From Apr 2024 to May 2024
Omega Diagnostics (LSE:ODX)
Historical Stock Chart
From May 2023 to May 2024